Liping Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Liping Chen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Bangshun He
Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China
1 shared publication - Ling Gu
College of Traditional Chinese Medicine & College of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China
1 shared publication - Qian Bao
Department of Life Sciences, Nanjing Normal University, Nanjing 210046, Jiangsu Province, China
1 shared publication - Shukui Wang
Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
1 shared publication - Yeqiong Xu
Central laboratory of Changshu Medical examination Institute, Changshu 215500, China
1 shared publication - Ying Zhang
Inspection Division, Kunshan Hospital Affiliated to Nanjing University of Chinese Medicine, Kunshan, 215300, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 12 July 2011
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 94
Effects of genetic variations in the Adiponectin pathway genes on the risk of colorectal cancer in the Chinese population
Background: Decreased expression of adiponectin (ADIPOQ) is associated with an increased risk for developing colorectal cancer (CRC) in humans. This study was designed to determine whether polymorphisms present in theADIPOQand its type 1 receptor (ADIPOR1) could affect the risk of CRC.Methods: We measured five polymorphisms in theADIPOQand two polymorphisms inADIPOR1, and analyzed their associations with CRC risk in 420 CRC patients and 555 age- and gender-matched healthy individuals.Results: Multivariate logistic regression analyses revealed that the CRC risks (adjusted odds ratio and 95% confidence interval) associated with theADIPOR1genotypes were 0.53 (95% CI, 0.35-0.81) for rs12733285C/T, 0.59 (95% CI, 0.45-0.78) for rs1342387A/G, and 0.59 (95% CI, 0.39-0.89) for rs1342387A/A, respectively. Furthermore, the risks were more significant in carriers of the allele A of rs1342387A/G (adjusted OR, 0.59; 95% CI, 0.46-0.77) than noncarriers (G/G). In a further subgroup analysis, we observed that rs266729G/C was associated with an increased risk for colon cancer (adjusted OR, 1.50; 95% CI, 1.05-2.14) but not for rectal cancer (adjusted OR, 0.88; 95% CI, 0.63-1.22), and that carriers of the G allele had an increased risk for developing colon cancer (adjusted OR, 1.45; 95% CI, 1.03-2.05).Conclusions: We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) inADIPOR1are the protective factors for CRC, while that rs266729G/C and G allele ofADIPOQare the risk factors for colon cancer after excluding rectal cancer cases.
- 12 July 2011
- Published by Springer Nature in BMC Medical Genetics
- Vol. 12 (1) , 94
Open AccessEffects of genetic variations in the Adiponectin pathway genes on the risk of colorectal cancer in the Chinese population
Background: Decreased expression of adiponectin (ADIPOQ) is associated with an increased risk for developing colorectal cancer (CRC) in humans. This study was designed to determine whether polymorphisms present in theADIPOQand its type 1 receptor (ADIPOR1) could affect the risk of CRC.Methods: We measured five polymorphisms in theADIPOQand two polymorphisms inADIPOR1, and analyzed their associations with CRC risk in 420 CRC patients and 555 age- and gender-matched healthy individuals.Results: Multivariate logistic regression analyses revealed that the CRC risks (adjusted odds ratio and 95% confidence interval) associated with theADIPOR1genotypes were 0.53 (95% CI, 0.35-0.81) for rs12733285C/T, 0.59 (95% CI, 0.45-0.78) for rs1342387A/G, and 0.59 (95% CI, 0.39-0.89) for rs1342387A/A, respectively. Furthermore, the risks were more significant in carriers of the allele A of rs1342387A/G (adjusted OR, 0.59; 95% CI, 0.46-0.77) than noncarriers (G/G). In a further subgroup analysis, we observed that rs266729G/C was associated with an increased risk for colon cancer (adjusted OR, 1.50; 95% CI, 1.05-2.14) but not for rectal cancer (adjusted OR, 0.88; 95% CI, 0.63-1.22), and that carriers of the G allele had an increased risk for developing colon cancer (adjusted OR, 1.45; 95% CI, 1.03-2.05).Conclusions: We conclude that the rs12733285C/T genotype and the carriage of the A allele of rs1342387 (A/G or A/A) inADIPOR1are the protective factors for CRC, while that rs266729G/C and G allele ofADIPOQare the risk factors for colon cancer after excluding rectal cancer cases.